Európska únia - slovenčina - EMA (European Medicines Agency)

zoetis belgium sa - meloxicam - oxicams - psy - zmiernenie zápalu a bolesti pri akútnych aj chronických muskuloskeletálnych ochoreniach u psov.

Európska únia - slovenčina - EMA (European Medicines Agency)

zoetis belgium sa - dibotermin alfa - kostné morfogenetické proteíny - psy - osteoindukčné činidlo na použitie pri liečbe zlomenín dlhých kostí ako doplnok k štandardnej chirurgickej starostlivosti s použitím redukcie otvorenej zlomeniny u psov.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

linde gas s.r.o., slovensko - kyslík - 87 - varia i

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

linde gas s.r.o., slovensko - kyslík - 87 - varia i

Európska únia - slovenčina - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - liečivá na dermatitídu okrem kortikosteroidov - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - drogy obštrukčnej choroby dýchacích ciest, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fridababy, llc 82 ne 26th street fl 33137 miami spojené štáty americké -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medexim, spol. s r.o. * < ul. hlboká 58 921 01 piešťany slovensko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

noxbox ltd. 1080-1081 galley drive, kent science park, me9 8ga sittingbourne, kent spojené kráľovstvo veľkej británie a severného Írska -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

flídr medical s.r.o. Široký dul 200 572 01 polička Česká republika -